51
Participants
Start Date
November 29, 2018
Primary Completion Date
July 14, 2025
Study Completion Date
October 3, 2026
Atezolizumab
Given IV
Biopsy Procedure
Undergo biopsy
Biospecimen Collection
Undergo collection of blood
Cobimetinib
Given PO
Computed Tomography
Undergo CT scan
Magnetic Resonance Imaging
Undergo MRI
NYP/Weill Cornell Medical Center, New York
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
MedStar Georgetown University Hospital, Washington D.C.
University of Virginia Cancer Center, Charlottesville
Wake Forest University at Clemmons, Clemmons
Wake Forest University Health Sciences, Winston-Salem
Hayworth Cancer Center, High Point
Emory University Hospital Midtown, Atlanta
Emory University Hospital/Winship Cancer Institute, Atlanta
Emory Saint Joseph's Hospital, Atlanta
Moffitt Cancer Center, Tampa
University of Alabama at Birmingham Cancer Center, Birmingham
Ohio State University Comprehensive Cancer Center, Columbus
Wayne State University/Karmanos Cancer Institute, Detroit
University of Oklahoma Health Sciences Center, Oklahoma City
UC San Diego Moores Cancer Center, La Jolla
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
Rutgers Cancer Institute of New Jersey, New Brunswick
National Cancer Institute (NCI)
NIH